3191 results for «372»
3191 results
Patient-tailored treatment for bicuspid valve
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into patient-tailored treatment strategies for bicuspid aortic valve stenosis, focusing on evidence-based valve selection and sizing for TAVI candidates. This session reviews current device options, procedural planning considerations, and case studies illustrating the use of balloon-expanding and self-expanding valves, emphasizing challenges posed by unfavourable bicuspid...
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the mitral TEER masterclass focusing on unique anatomical challenges encountered in Asian populations. This session presents complex case studies illustrating device strategies and practical techniques aimed at minimizing complications and optimizing procedural outcomes in anatomically challenging scenarios.
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session on redo Transcatheter Aortic Valve Implantation (TAVI) covers critical aspects beyond coronary obstruction risk, including detailed pre-procedural analysis, valve sizing, and innovative procedural techniques such as leaflet modification and optimal angle placement. Post-procedural considerations like antithrombotic therapy and patient-prosthesis mismatch are also thoroughly...
Contemporary approach in the treatment of calcified coronary artery disease
28 Feb 2026 – From Euro4C Annual Meeting 2026
Adopt a contemporary approach to managing calcified coronary artery disease by leveraging high-definition IVUS for lesion assessment and morphology evaluation. Learn to tailor calcium modification strategies based on IVUS findings and combine available tools to optimize treatment outcomes according to patient and lesion profiles.
Welcome to the Euro4C Annual Meeting 2026
27 Feb 2026 – From Euro4C Annual Meeting 2026
This introductory session sets the stage for a comprehensive exploration of interventional cardiology topics, providing attendees with an overview and framework for the upcoming educational content.
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial
26 Oct 2023
Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial
Author
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
22 Mar 2022
Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.
Author
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.
Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.
Author
Author
